GlobalData on MSN1d
USPTO grants patent to Vistagen’s neuropathic pain treatment
The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...
JD Supra2d
UPC Court of Appeal confirms strict approach to correcting patent errors by interpretation
Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.
JD Supra7h
USPTO’s Proposed Terminal Disclaimer Practice
On May 10, 2024, the United States Patent and Trademark Office (“USPTO”) published a new proposed rule that would require when a patent ...
Aprea Therapeutics provides update on existing patent portfolio
Aprea Therapeutics (APRE) provided an update on its existing patent portfolio. Aprea’s ATR inhibitor program is protected by ...
Annual Anaqua Analysis of USPTO Data Finds Strong Increase in Patent Grant Activity
AI patent grants grew in overall volume for the fourth year – increasing from 34,544 in 2020 to 54,022 in 2024 – with innovations in biological-related AI, machine learning AI, image or voice ...
IPWatchdog4d
Bad Patents, Thwarted Patent Reform, and a Failure to Adapt
This week we speak with Scott McKeown, who is a shareholder at Wolf Greenfield and one of the leading U.S. PTAB practitioners ...
Vistagen granted USPTO patent for AV-101 to treat neuropathic pain
Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...